Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine

American Journal of Hematology

Volumn 90, Issue 2, 2015, Pages 91-96

  Pennell, Dudley J ^a   Porter, John B ^b   Piga, Antonio ^c   Lai, Yong Rong ^d   El Beshlawy, Amal ^e   Elalfy, Mohsen ^f   Yesilipek, Akif ^g   Kilinç, Yurdanur ^h   Habr, Dany ⁱ   Musallam, Khaled M ⁱ   Shen, Junwu ⁱ   Aydinok, Yesim ^j  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF TURIN   (Italy)

^d FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^e CAIRO UNIVERSITY   (Egypt)

^f AIN SHAMS UNIVERSITY   (Egypt)

^g AKDENIZ UNIVERSITY   (Turkey)

^h CUKUROVA UNIVERSITY   (Turkey)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; DEFERASIROX; DEFEROXAMINE; FERRITIN; IRON; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; HEART HEMOSIDEROSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTRANSAMINASEMIA; IRON CHELATION; IRON INTAKE; IRON OVERLOAD; IRON STORAGE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THALASSEMIA MAJOR; TREATMENT DURATION; YOUNG ADULT; ADVERSE EFFECTS; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; CLINICAL TRIAL; HEART MUSCLE; LIVER; METABOLISM; PATHOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BENZOATES; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; DEFEROXAMINE; FEMALE; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MALE; MYOCARDIUM; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84921325842     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23876     Document Type: Article

References (28)

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-1193.
2. Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: Data from the UK Thalassaemia Register. Lancet 2000;355:2051-2052.
3. Gujja P, Rosing DR, Tripodi DJ, Shizukuda Y. Iron overload cardiomyopathy: Better understanding of an increasing disorder. J Am Coll Cardiol 2010;56:1001-1012.
4. Fernandes JL, Fabron A, Jr., Verissimo M. Early cardiac iron overload in children with transfusion-dependent anemias. Haematologica 2009;94:1776-1777.
5. Noetzli LJ, Carson SM, Nord AS, et al. Longitudinal analysis of heart and liver iron in thalassemia major. Blood 2008;112:2973-2978.
6. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2* -star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-2179.
7. Pennell D, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* * in patients with beta-thalassemia major. Haematologica 2012;97:842-848.
8. Pennell DJ, Porter JB, Piga A, et al. A 1-year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA). Blood 2014;123:1447-1454.
9. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107:3738-3744.
10. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876-1884.
11. Pepe A, Lombardi M, Positano V, et al. Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2* *. Eur J Haematol 2006;76:183-192.
12. Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008;10:12.
13. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010;116:537-543.
14. ®) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Ann Hematol 2010;89:405-409.
15. Wood JC, Glynos T, Thompson A, et al. Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial. Am J Hematol 2010;85:818-819.
16. Carpenter J-P, He T, Kirk P, et al. On T2* magnetic resonance and cardiac iron. Circulation 2011;123:1519-1528.
17. Pennell DJ, Udelson JE, Arai AE, et al. Cardiovascular function and treatment in beta-thalassemia major: A consensus statement from the American Heart Association. Circulation 2013;128:281-308.
18. Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2* over 2 years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica 2011;96:48-54.
19. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: A prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004;127:348-355.
20. Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009;120:1961-1968.
21. Deugnier Y, Turlin B, Ropert M, et al. Improvement in liver pathology of patients with beta-thalassemia treated with deferasirox for at least 3 years. Gastroenterology 2011;141:1202-1211.
22. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994;331:574-578.
23. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
24. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002;100:17-21.
25. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-573.
26. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood 2010;115:2364-2371.
27. Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy and safety during 5 years' follow-up. Blood 2011;118:884-893.
28. Thalassaemia International Federation. Guidelines for the clinical management of thalassaemia, 2nd Revised Edition. 2008. Available at: http://www.thalassaemia.org.cy/wp-content/uploads/pdf/educational-programmes/Publications/Guidelines%20%282008%29/Thalassaemia%20Guidelines%20ENGLISH.pdf.